View Clinical Trial (Medical Research Study)
Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents - NCT01177969-(Clinical Trial 721803)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Los Angeles |
|
State:
|
|
CA |
| Zip Code: |
|
|
| Conditions: |
|
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified |
| Purpose: |
|
Comorbid anxiety disorders affect as many as 80% of youth with autism spectrum disorders,
causing substantial distress and impairment over and above the autism spectrum diagnosis
alone. Cognitive behavioral therapy (CBT) is the gold standard treatment among typically
developing youth with an anxiety disorder and when adapted, shows promise in children with
ASD and comorbid anxiety. However, there is currently no psychotherapy protocol tailored to
meet the unique needs of young adolescents with Autism spectrum disorders (ASD) and comorbid
anxiety. Given this, the present study seeks to develop and test a new CBT therapy in
adolescents with autism and comorbid anxiety.
|
| Study summary: |
|
Autism spectrum disorders (ASD) affect approximately 1 out of 150 children and adolescents
in the United States, making them one of the most common neurobiological conditions.
Comorbid anxiety disorders affect as many as 80% of youth with ASD, causing substantial
distress and impairment over and above that caused by an ASD diagnosis alone. While
cognitive-behavioral therapy (CBT) has been established as the gold standard treatment for
anxiety disorders among typically developing youth, a protocol does not exist for early
adolescents with ASD and comorbid anxiety disorders. Accordingly, we are proposing to
develop a CBT protocol for anxiety and comorbid ASD in early adolescence.
Initial protocol development efforts will focus on adapting relevant treatment elements from
an effective CBT program for younger children with ASD and comorbid anxiety to the
characteristics and clinical needs of early adolescents. Thereafter, protocol and measure
development will be refined during Phases I and II of this study through our experiences
treating a total of 20 young adolescents (ages 11-14 years - 10 will be treated at USF; 10
at University of California, Los Angeles (UCLA)) with ASD and comorbid anxiety disorder(s).
The CBT protocol will then be examined in a trial comparing CBT to a waitlist condition (N =
32 total; 16 at each study site).
The two recruitment sites for this study are the University of California, Los Angeles and
the University of South Florida. The University of Miami will assist with quality assurance
checks. Considering the rising number of youth diagnosed with ASD, and the lack of tested
treatment options for those young adolescents with comorbid anxiety, our proposed work
toward an efficacious CBT protocol will provide a timely contribution to public health
efforts. |
| Criteria: |
|
Inclusion Criteria:
- Outpatient adolescents with ASD (see below) between the ages 11-14 years.
- Meets criteria for a diagnosis of autism, Asperger syndrome (AS), or Pervasive
Developmental Disorder Not Otherwise Specified .
- Meets criteria for a diagnosis of one of the following anxiety disorders: separation
anxiety disorder (SAD), generalized anxiety disorder (GAD), social phobia, or
obsessive compulsive disorder (OCD).
- Child has a Full Scale and Verbal Comprehension IQ≥85.
Exclusion Criteria:
- Receiving concurrent psychotherapy, social skills training, or behavioral
interventions (e.g., applied behavior analysis). Families will have the option of
discontinuing such services to enroll in the study.
- Has started an antidepressant within 12 weeks before study enrollment or an
antipsychotic 6 weeks before study enrollment.
- Has changed established psychotropic medications (e.g., antidepressants,
anxioloytics) within 8 weeks before study enrollment (6 weeks for antipsychotic).
- Is currently suicidal or has been actively suicidal in the last 6 months.
- Has been diagnosed with bipolar, schizophrenia or schizoaffective disorders; or
Substance abuse in past 6 months.
- Presence of a significant and/or unstable medical illness which might lead to
hospitalization during the study. |
|
|
|
| Study is available at: |
|
Univeristy of California at Los Angeles Los Angeles, CA United States
Primary Contact: Eric Storch, Ph.D. Email: estorch@health.usf.edu Phone: 727-767-8230 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|